Microalbuminuria as a target to improve cardiovascular and renal outcomes

被引：86

作者：

Basi, Seema ^{[1
]}

Lewis, Julia B. ^{[1
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Dept Med, Div Nephrol, Nashville, TN 37232 USA

来源：

AMERICAN JOURNAL OF KIDNEY DISEASES | 2006年 / 47卷 / 06期

关键词：

microalbuminuria; kidney disease; cardiovascular disease; angiotensin-converting enzyme inhibitor; angiotensin II receptor antagonist;

D O I：

10.1053/j.ajkd.2006.02.182

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Albuminuria is a cardiovascular and renal risk factor in patients with diabetes, patients with hypertension, and the general population. Risk has been shown to increase continuously with increasing urinary albumin levels, starting at levels that once were considered normal. This association is maintained even after adjusting for numerous other factors. Studies also established that a decrease in albuminuria leads to improvement in both cardiovascular and renal outcomes. These data suggest that urinary albumin should be measured routinely and treated to afford cardiovascular and renoprotection.

引用

页码：927 / 946

页数：20

共 107 条

[71] RETRACTED: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial (Retracted article. See vol. 374, pg. 1226, 2009) [J].

Nakao, N ;

Yoshimura, A ;

Morita, H ;

Takada, M ;

Kayano, T ;

Ideura, T .

LANCET, 2003, 361 (9352) :117-124

[72] Central role of the AT1-receptor in atherosclerosis [J].

Nickenig, G .

JOURNAL OF HUMAN HYPERTENSION, 2002, 16 (Suppl 3) :S26-S33

[73]

Nosadini R, 2003, J NEPHROL, V16, pS42

[74] Effect of losairtan versus atenolol on aortic valve sclerosis (a LIFE substudy) [J].

Olsen, MH ;

Wachtell, K ;

Bella, JN ;

Liu, JE ;

Boman, K ;

Gerdts, E ;

Papademetriou, V ;

Nieminen, MS ;

Rokkedal, J ;

Dahlöf, B ;

Devereux, RB .

AMERICAN JOURNAL OF CARDIOLOGY, 2004, 94 (08) :1076-1080

[75] EARLY DETECTION OF PATIENTS AT RISK OF DEVELOPING DIABETIC NEPHROPATHY - A LONGITUDINAL-STUDY OF URINARY ALBUMIN EXCRETION [J].

PARVING, HH ;

OXENBOLL, B ;

SVENDSEN, PA ;

CHRISTIANSEN, JS ;

ANDERSEN, AR .

ACTA ENDOCRINOLOGICA, 1982, 100 (04) :550-555

[76] The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes [J].

Parving, HH ;

Lehnert, H ;

Bröchner-Mortensen, J ;

Gomis, R ;

Andersen, S ;

Arner, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :870-878

[77]

PARVING HH, 2006, IN PRESS KIDNEY INT

[78] Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats [J].

Pilz, B ;

Shagdarsuren, E ;

Wellner, M ;

Fiebeler, A ;

Dechend, R ;

Gratze, P ;

Meiners, S ;

Feldman, DL ;

Webb, RL ;

Garrelds, IM ;

Danser, AHJ ;

Luft, FC ;

Müller, DN .

HYPERTENSION, 2005, 46 (03) :569-576

[79] Prevalence and clinical correlates of microalbuminuria in essential hypertension - The MAGIC study [J].

Pontremoli, R ;

Sofia, A ;

Ravera, M ;

Nicolella, C ;

Viazzi, F ;

Tirotta, A ;

Ruello, N ;

Tomolillo, C ;

Castello, C ;

Grillo, G ;

Sacchi, G ;

Deferrari, G .

HYPERTENSION, 1997, 30 (05) :1135-1143

[80] Microalbuminuria, cardiovascular, and renal risk in primary hypertension [J].

Pontremoli, R ;

Leoncini, G ;

Ravera, M ;

Viazzi, F ;

Vettoretti, S ;

Ratto, E ;

Parodi, D ;

Tomolillo, C ;

Deferrari, G .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (11) :S169-S172

← 2 3 4 5 6 7 8 9 10 11 →